#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=In this study , exposure to ERAV , as determined by serological testing , was associated with respiratory disease , loss of training days and failure to race in young racehorses .
3-1	15-17	In	_	_	_	_
3-2	18-22	this	abstract[3]	new[3]	coref	7-2[35_3]
3-3	23-28	study	abstract[3]	new[3]	_	_
3-4	29-30	,	_	_	_	_
3-5	31-39	exposure	abstract[4]	new[4]	coref	21-3[159_4]
3-6	40-42	to	abstract[4]	new[4]	_	_
3-7	43-47	ERAV	abstract[4]|abstract	new[4]|new	coref	4-13
3-8	48-49	,	_	_	_	_
3-9	50-52	as	_	_	_	_
3-10	53-63	determined	_	_	_	_
3-11	64-66	by	_	_	_	_
3-12	67-78	serological	abstract[6]	new[6]	_	_
3-13	79-86	testing	abstract[6]	new[6]	_	_
3-14	87-88	,	_	_	_	_
3-15	89-92	was	_	_	_	_
3-16	93-103	associated	_	_	_	_
3-17	104-108	with	_	_	_	_
3-18	109-120	respiratory	abstract[7]|abstract[8]	new[7]|new[8]	coref|coref|coref|coref	13-1[87_7]|16-9[112_8]|13-1[87_7]|16-9[112_8]
3-19	121-128	disease	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-20	129-130	,	abstract[8]	new[8]	_	_
3-21	131-135	loss	abstract[8]|abstract[9]	new[8]|new[9]	coref	16-13[114_9]
3-22	136-138	of	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-23	139-147	training	abstract[8]|abstract[9]|abstract|event[11]	new[8]|new[9]|new|new[11]	coref|coref	5-10|5-10
3-24	148-152	days	abstract[8]|abstract[9]|event[11]	new[8]|new[9]|new[11]	_	_
3-25	153-156	and	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-26	157-164	failure	abstract[8]|abstract[9]|abstract[12]	new[8]|new[9]|new[12]	coref	9-21[64_12]
3-27	165-167	to	abstract[8]|abstract[9]|abstract[12]	new[8]|new[9]|new[12]	_	_
3-28	168-172	race	abstract[8]|abstract[9]|abstract[12]|abstract[13]	new[8]|new[9]|new[12]|new[13]	coref	5-30[27_13]
3-29	173-175	in	abstract[8]|abstract[9]|abstract[12]|abstract[13]	new[8]|new[9]|new[12]|new[13]	_	_
3-30	176-181	young	abstract[8]|abstract[9]|abstract[12]|abstract[13]|animal[14]	new[8]|new[9]|new[12]|new[13]|new[14]	coref	7-7[36_14]
3-31	182-192	racehorses	abstract[8]|abstract[9]|abstract[12]|abstract[13]|animal[14]	new[8]|new[9]|new[12]|new[13]|new[14]	_	_
3-32	193-194	.	_	_	_	_

#Text=Monthly screening indicated that the majority of two-year-old horses were exposed to ERAV during the three months after entering the yard .
4-1	195-202	Monthly	abstract[15]	new[15]	_	_
4-2	203-212	screening	abstract[15]	new[15]	_	_
4-3	213-222	indicated	_	_	_	_
4-4	223-227	that	_	_	_	_
4-5	228-231	the	animal[16]	new[16]	coref	5-15[23_16]
4-6	232-240	majority	animal[16]	new[16]	_	_
4-7	241-243	of	animal[16]	new[16]	_	_
4-8	244-256	two-year-old	animal[16]	new[16]	_	_
4-9	257-263	horses	animal[16]	new[16]	_	_
4-10	264-268	were	_	_	_	_
4-11	269-276	exposed	_	_	_	_
4-12	277-279	to	_	_	_	_
4-13	280-284	ERAV	abstract	giv	coref	7-18
4-14	285-291	during	_	_	_	_
4-15	292-295	the	time[18]	new[18]	_	_
4-16	296-301	three	time[18]	new[18]	_	_
4-17	302-308	months	time[18]	new[18]	_	_
4-18	309-314	after	_	_	_	_
4-19	315-323	entering	_	_	_	_
4-20	324-327	the	place[19]	new[19]	coref	5-20[24_19]
4-21	328-332	yard	place[19]	new[19]	_	_
4-22	333-334	.	_	_	_	_

#Text=The clinical signs that resulted in an interruption to training were primarily observed after the horses had been in the yard for several weeks and were being prepared for their first race .
5-1	335-338	The	abstract[20]	new[20]	coref	15-1[104_20]
5-2	339-347	clinical	abstract[20]	new[20]	_	_
5-3	348-353	signs	abstract[20]	new[20]	_	_
5-4	354-358	that	_	_	_	_
5-5	359-367	resulted	abstract	new	coref|none	12-1[78_0]|5-5[0_192]
5-6	368-370	in	_	_	_	_
5-7	371-373	an	abstract[21]	new[21]	coref	12-13[82_21]
5-8	374-386	interruption	abstract[21]	new[21]	_	_
5-9	387-389	to	_	_	_	_
5-10	390-398	training	abstract	giv	coref	7-42[47_0]
5-11	399-403	were	_	_	_	_
5-12	404-413	primarily	_	_	_	_
5-13	414-422	observed	_	_	_	_
5-14	423-428	after	_	_	_	_
5-15	429-432	the	animal[23]	giv[23]	coref	6-4[29_23]
5-16	433-439	horses	animal[23]	giv[23]	_	_
5-17	440-443	had	_	_	_	_
5-18	444-448	been	_	_	_	_
5-19	449-451	in	_	_	_	_
5-20	452-455	the	place[24]	giv[24]	coref	8-5[51_24]
5-21	456-460	yard	place[24]	giv[24]	_	_
5-22	461-464	for	place[24]	giv[24]	_	_
5-23	465-472	several	place[24]|time[25]	giv[24]|new[25]	ana	5-30[0_25]
5-24	473-478	weeks	place[24]|time[25]	giv[24]|new[25]	_	_
5-25	479-482	and	_	_	_	_
5-26	483-487	were	_	_	_	_
5-27	488-493	being	_	_	_	_
5-28	494-502	prepared	_	_	_	_
5-29	503-506	for	_	_	_	_
5-30	507-512	their	time|abstract[27]	giv|giv[27]	coref|coref	9-23[0_27]|9-23[0_27]
5-31	513-518	first	abstract[27]	giv[27]	_	_
5-32	519-523	race	abstract[27]	giv[27]	_	_
5-33	524-525	.	_	_	_	_

#Text=The susceptibility of young horses to rhinitis virus infection when moved to a new environment and starting to comingle with other horses has been reported previously .
6-1	526-529	The	abstract[28]	new[28]	coref	21-22[167_28]
6-2	530-544	susceptibility	abstract[28]	new[28]	_	_
6-3	545-547	of	abstract[28]	new[28]	_	_
6-4	548-553	young	abstract[28]|animal[29]	new[28]|giv[29]	coref	6-21[34_29]
6-5	554-560	horses	abstract[28]|animal[29]	new[28]|giv[29]	_	_
6-6	561-563	to	abstract[28]|animal[29]	new[28]|giv[29]	_	_
6-7	564-572	rhinitis	abstract[28]|animal[29]|abstract|abstract[32]	new[28]|giv[29]|new|new[32]	coref|coref	8-12[54_32]|8-12[54_32]
6-8	573-578	virus	abstract[28]|animal[29]|abstract|abstract[32]	new[28]|giv[29]|new|new[32]	_	_
6-9	579-588	infection	abstract[28]|animal[29]|abstract[32]	new[28]|giv[29]|new[32]	_	_
6-10	589-593	when	_	_	_	_
6-11	594-599	moved	_	_	_	_
6-12	600-602	to	_	_	_	_
6-13	603-604	a	abstract[33]	new[33]	coref	21-14[0_33]
6-14	605-608	new	abstract[33]	new[33]	_	_
6-15	609-620	environment	abstract[33]	new[33]	_	_
6-16	621-624	and	_	_	_	_
6-17	625-633	starting	_	_	_	_
6-18	634-636	to	_	_	_	_
6-19	637-645	comingle	_	_	_	_
6-20	646-650	with	_	_	_	_
6-21	651-656	other	animal[34]	giv[34]	coref	7-14[0_34]
6-22	657-663	horses	animal[34]	giv[34]	_	_
6-23	664-667	has	_	_	_	_
6-24	668-672	been	_	_	_	_
6-25	673-681	reported	_	_	_	_
6-26	682-692	previously	_	_	_	_
6-27	693-694	.	_	_	_	_

#Text=In a seven-year serological study of racehorses in Japan , 69 % of horses that seroconverted to ERAV were two years of age and Black et al. reported that 43 % of horses seroconverted to ERAV within 7 months of entering a training stable in Australia .
7-1	695-697	In	_	_	_	_
7-2	698-699	a	abstract[35]	giv[35]	coref	8-1[49_35]
7-3	700-710	seven-year	abstract[35]	giv[35]	_	_
7-4	711-722	serological	abstract[35]	giv[35]	_	_
7-5	723-728	study	abstract[35]	giv[35]	_	_
7-6	729-731	of	abstract[35]	giv[35]	_	_
7-7	732-742	racehorses	abstract[35]|animal[36]	giv[35]|giv[36]	coref	18-12[135_36]
7-8	743-745	in	abstract[35]|animal[36]	giv[35]|giv[36]	_	_
7-9	746-751	Japan	abstract[35]|animal[36]|place	giv[35]|giv[36]|new	_	_
7-10	752-753	,	_	_	_	_
7-11	754-756	69	quantity[38]	new[38]	_	_
7-12	757-758	%	quantity[38]	new[38]	_	_
7-13	759-761	of	quantity[38]	new[38]	_	_
7-14	762-768	horses	quantity[38]|animal	new[38]|giv	coref	7-33
7-15	769-773	that	_	_	_	_
7-16	774-787	seroconverted	_	_	_	_
7-17	788-790	to	_	_	_	_
7-18	791-795	ERAV	abstract	giv	coref	7-36
7-19	796-800	were	_	_	_	_
7-20	801-804	two	time[41]	new[41]	_	_
7-21	805-810	years	time[41]	new[41]	_	_
7-22	811-813	of	time[41]	new[41]	_	_
7-23	814-817	age	time[41]|abstract	new[41]|new	_	_
7-24	818-821	and	time[41]	new[41]	_	_
7-25	822-827	Black	time[41]	new[41]	_	_
7-26	828-830	et	time[41]	new[41]	_	_
7-27	831-834	al.	time[41]	new[41]	_	_
7-28	835-843	reported	_	_	_	_
7-29	844-848	that	_	_	_	_
7-30	849-851	43	quantity[43]	new[43]	_	_
7-31	852-853	%	quantity[43]	new[43]	_	_
7-32	854-856	of	quantity[43]	new[43]	_	_
7-33	857-863	horses	quantity[43]|animal	new[43]|giv	coref	8-18[55_0]
7-34	864-877	seroconverted	_	_	_	_
7-35	878-880	to	_	_	_	_
7-36	881-885	ERAV	abstract	giv	coref	8-12
7-37	886-892	within	_	_	_	_
7-38	893-894	7	time[46]	new[46]	_	_
7-39	895-901	months	time[46]	new[46]	_	_
7-40	902-904	of	_	_	_	_
7-41	905-913	entering	_	_	_	_
7-42	914-915	a	abstract[47]	giv[47]	coref	8-6[0_47]
7-43	916-924	training	abstract[47]	giv[47]	_	_
7-44	925-931	stable	_	_	_	_
7-45	932-934	in	_	_	_	_
7-46	935-944	Australia	place	new	coref	28-8
7-47	945-946	.	_	_	_	_

#Text=A previous study in a training yard in Ireland indicated that ERAV infection was largely confined to two-year-old horses and was most prevalent in late winter and spring .
8-1	947-948	A	abstract[49]	giv[49]	coref	10-8[68_49]
8-2	949-957	previous	abstract[49]	giv[49]	_	_
8-3	958-963	study	abstract[49]	giv[49]	_	_
8-4	964-966	in	abstract[49]	giv[49]	_	_
8-5	967-968	a	abstract[49]|place[51]	giv[49]|giv[51]	coref	25-10[194_51]
8-6	969-977	training	abstract[49]|abstract|place[51]	giv[49]|giv|giv[51]	coref	9-18[63_0]
8-7	978-982	yard	abstract[49]|place[51]	giv[49]|giv[51]	_	_
8-8	983-985	in	abstract[49]|place[51]	giv[49]|giv[51]	_	_
8-9	986-993	Ireland	abstract[49]|place[51]|place	giv[49]|giv[51]|new	coref	28-6
8-10	994-1003	indicated	_	_	_	_
8-11	1004-1008	that	_	_	_	_
8-12	1009-1013	ERAV	object|abstract[54]	giv|giv[54]	ana|coref|ana|coref	5-5[0_54]|9-15|5-5[0_54]|9-15
8-13	1014-1023	infection	abstract[54]	giv[54]	_	_
8-14	1024-1027	was	_	_	_	_
8-15	1028-1035	largely	_	_	_	_
8-16	1036-1044	confined	_	_	_	_
8-17	1045-1047	to	_	_	_	_
8-18	1048-1060	two-year-old	animal[55]	giv[55]	coref	12-19[85_55]
8-19	1061-1067	horses	animal[55]	giv[55]	_	_
8-20	1068-1071	and	_	_	_	_
8-21	1072-1075	was	_	_	_	_
8-22	1076-1080	most	_	_	_	_
8-23	1081-1090	prevalent	_	_	_	_
8-24	1091-1093	in	_	_	_	_
8-25	1094-1098	late	time[56]	new[56]	_	_
8-26	1099-1105	winter	time[56]	new[56]	_	_
8-27	1106-1109	and	_	_	_	_
8-28	1110-1116	spring	time	new	coref	10-23[73_0]
8-29	1117-1118	.	_	_	_	_

#Text=However , we believe that this is the first investigation of the association between ERAV infection with interrupted training and failure to race .
9-1	1119-1126	However	_	_	_	_
9-2	1127-1128	,	_	_	_	_
9-3	1129-1131	we	person	acc	_	_
9-4	1132-1139	believe	_	_	_	_
9-5	1140-1144	that	_	_	_	_
9-6	1145-1149	this	abstract	giv	coref	9-8[60_0]
9-7	1150-1152	is	_	_	_	_
9-8	1153-1156	the	abstract[60]	giv[60]	coref	13-6[89_60]
9-9	1157-1162	first	abstract[60]	giv[60]	_	_
9-10	1163-1176	investigation	abstract[60]	giv[60]	_	_
9-11	1177-1179	of	abstract[60]	giv[60]	_	_
9-12	1180-1183	the	abstract[60]|abstract[61]	giv[60]|new[61]	coref	19-19[143_61]
9-13	1184-1195	association	abstract[60]|abstract[61]	giv[60]|new[61]	_	_
9-14	1196-1203	between	abstract[60]|abstract[61]	giv[60]|new[61]	_	_
9-15	1204-1208	ERAV	abstract[60]|abstract[61]|object	giv[60]|new[61]|giv	coref	10-12
9-16	1209-1218	infection	abstract[60]|abstract[61]	giv[60]|new[61]	_	_
9-17	1219-1223	with	abstract[60]|abstract[61]	giv[60]|new[61]	_	_
9-18	1224-1235	interrupted	abstract[60]|abstract[61]|abstract[63]	giv[60]|new[61]|giv[63]	coref	12-16[0_63]
9-19	1236-1244	training	abstract[60]|abstract[61]|abstract[63]	giv[60]|new[61]|giv[63]	_	_
9-20	1245-1248	and	abstract[60]|abstract[61]	giv[60]|new[61]	_	_
9-21	1249-1256	failure	abstract[60]|abstract[61]|abstract[64]	giv[60]|new[61]|giv[64]	coref	19-26[145_64]
9-22	1257-1259	to	abstract[60]|abstract[61]|abstract[64]	giv[60]|new[61]|giv[64]	_	_
9-23	1260-1264	race	abstract[60]|abstract[61]|abstract[64]|abstract	giv[60]|new[61]|giv[64]|giv	coref	19-28[146_0]
9-24	1265-1266	.	_	_	_	_

#Text=Over 55 % of the two-year-olds in the study seroconverted to ERAV in May and June and none of them raced at that time .
10-1	1267-1271	Over	quantity[66]	new[66]	_	_
10-2	1272-1274	55	quantity[66]	new[66]	_	_
10-3	1275-1276	%	quantity[66]	new[66]	_	_
10-4	1277-1279	of	quantity[66]	new[66]	_	_
10-5	1280-1283	the	quantity[66]|abstract[67]	new[66]|new[67]	ana	10-20[0_67]
10-6	1284-1297	two-year-olds	quantity[66]|abstract[67]	new[66]|new[67]	_	_
10-7	1298-1300	in	quantity[66]|abstract[67]	new[66]|new[67]	_	_
10-8	1301-1304	the	quantity[66]|abstract[67]|abstract[68]	new[66]|new[67]|giv[68]	coref	12-4[79_68]
10-9	1305-1310	study	quantity[66]|abstract[67]|abstract[68]	new[66]|new[67]|giv[68]	_	_
10-10	1311-1324	seroconverted	_	_	_	_
10-11	1325-1327	to	_	_	_	_
10-12	1328-1332	ERAV	abstract	giv	coref	12-11
10-13	1333-1335	in	_	_	_	_
10-14	1336-1339	May	time	new	_	_
10-15	1340-1343	and	_	_	_	_
10-16	1344-1348	June	_	_	_	_
10-17	1349-1352	and	_	_	_	_
10-18	1353-1357	none	event[71]	new[71]	_	_
10-19	1358-1360	of	event[71]	new[71]	_	_
10-20	1361-1365	them	event[71]|abstract	new[71]|giv	coref	11-8[75_0]
10-21	1366-1371	raced	_	_	_	_
10-22	1372-1374	at	_	_	_	_
10-23	1375-1379	that	time[73]	giv[73]	_	_
10-24	1380-1384	time	time[73]	giv[73]	_	_
10-25	1385-1386	.	_	_	_	_

#Text=In fact , only 29 % of the two-year-olds raced in their first season .
11-1	1387-1389	In	_	_	_	_
11-2	1390-1394	fact	_	_	_	_
11-3	1395-1396	,	_	_	_	_
11-4	1397-1401	only	quantity[74]	new[74]	coref	28-21[224_74]
11-5	1402-1404	29	quantity[74]	new[74]	_	_
11-6	1405-1406	%	quantity[74]	new[74]	_	_
11-7	1407-1409	of	quantity[74]	new[74]	_	_
11-8	1410-1413	the	quantity[74]|abstract[75]	new[74]|giv[75]	ana	11-12[0_75]
11-9	1414-1427	two-year-olds	quantity[74]|abstract[75]	new[74]|giv[75]	_	_
11-10	1428-1433	raced	_	_	_	_
11-11	1434-1436	in	_	_	_	_
11-12	1437-1442	their	abstract|time[77]	giv|new[77]	coref|coref	19-30[148_77]|19-30[148_77]
11-13	1443-1448	first	time[77]	new[77]	_	_
11-14	1449-1455	season	time[77]	new[77]	_	_
11-15	1456-1457	.	_	_	_	_

#Text=The results of this study suggest that the importance of ERAV in the interruption of training programmes for young horses may be underestimated .
12-1	1458-1461	The	abstract[78]	new[78]	coref	25-1[192_78]
12-2	1462-1469	results	abstract[78]	new[78]	_	_
12-3	1470-1472	of	abstract[78]	new[78]	_	_
12-4	1473-1477	this	abstract[78]|abstract[79]	new[78]|giv[79]	coref	14-2[90_79]
12-5	1478-1483	study	abstract[78]|abstract[79]	new[78]|giv[79]	_	_
12-6	1484-1491	suggest	_	_	_	_
12-7	1492-1496	that	_	_	_	_
12-8	1497-1500	the	abstract[80]	new[80]	_	_
12-9	1501-1511	importance	abstract[80]	new[80]	_	_
12-10	1512-1514	of	abstract[80]	new[80]	_	_
12-11	1515-1519	ERAV	abstract[80]|abstract	new[80]|giv	coref	13-6
12-12	1520-1522	in	abstract[80]	new[80]	_	_
12-13	1523-1526	the	abstract[80]|abstract[82]	new[80]|giv[82]	coref	20-17[0_82]
12-14	1527-1539	interruption	abstract[80]|abstract[82]	new[80]|giv[82]	_	_
12-15	1540-1542	of	abstract[80]|abstract[82]	new[80]|giv[82]	_	_
12-16	1543-1551	training	abstract[80]|abstract[82]|abstract|abstract[84]	new[80]|giv[82]|giv|new[84]	coref|coref	16-14|16-14
12-17	1552-1562	programmes	abstract[80]|abstract[82]|abstract[84]	new[80]|giv[82]|new[84]	_	_
12-18	1563-1566	for	abstract[80]|abstract[82]|abstract[84]	new[80]|giv[82]|new[84]	_	_
12-19	1567-1572	young	abstract[80]|abstract[82]|abstract[84]|animal[85]	new[80]|giv[82]|new[84]|giv[85]	coref	22-4[169_85]
12-20	1573-1579	horses	abstract[80]|abstract[82]|abstract[84]|animal[85]	new[80]|giv[82]|new[84]|giv[85]	_	_
12-21	1580-1583	may	_	_	_	_
12-22	1584-1586	be	_	_	_	_
12-23	1587-1601	underestimated	_	_	_	_
12-24	1602-1603	.	_	_	_	_

#Text=Acute febrile respiratory disease following ERAV infection has been reported previously .
13-1	1604-1609	Acute	abstract[87]	giv[87]	coref	14-9[93_87]
13-2	1610-1617	febrile	object|abstract[87]	new|giv[87]	_	_
13-3	1618-1629	respiratory	abstract[87]	giv[87]	_	_
13-4	1630-1637	disease	abstract[87]	giv[87]	_	_
13-5	1638-1647	following	_	_	_	_
13-6	1648-1652	ERAV	object|abstract[89]	giv|giv[89]	coref|coref|coref|coref	16-1|19-7[140_89]|16-1|19-7[140_89]
13-7	1653-1662	infection	abstract[89]	giv[89]	_	_
13-8	1663-1666	has	_	_	_	_
13-9	1667-1671	been	_	_	_	_
13-10	1672-1680	reported	_	_	_	_
13-11	1681-1691	previously	_	_	_	_
13-12	1692-1693	.	_	_	_	_

#Text=In an experimental study , ERAV-inoculated ponies developed respiratory tract disease characterized by pyrexia , nasal discharge , adventitious lung sounds , and enlarged mandibular lymph nodes , which corresponded with an increase in antibody titres against the virus .
14-1	1694-1696	In	_	_	_	_
14-2	1697-1699	an	abstract[90]	giv[90]	coref	15-6[105_90]
14-3	1700-1712	experimental	abstract[90]	giv[90]	_	_
14-4	1713-1718	study	abstract[90]	giv[90]	_	_
14-5	1719-1720	,	_	_	_	_
14-6	1721-1736	ERAV-inoculated	animal[91]	new[91]	_	_
14-7	1737-1743	ponies	animal[91]	new[91]	_	_
14-8	1744-1753	developed	_	_	_	_
14-9	1754-1765	respiratory	abstract[93]	giv[93]	coref	14-38[103_93]
14-10	1766-1771	tract	object|abstract[93]	new|giv[93]	_	_
14-11	1772-1779	disease	abstract[93]	giv[93]	_	_
14-12	1780-1793	characterized	_	_	_	_
14-13	1794-1796	by	_	_	_	_
14-14	1797-1804	pyrexia	abstract	new	_	_
14-15	1805-1806	,	_	_	_	_
14-16	1807-1812	nasal	substance[95]	new[95]	_	_
14-17	1813-1822	discharge	substance[95]	new[95]	_	_
14-18	1823-1824	,	_	_	_	_
14-19	1825-1837	adventitious	abstract[97]	new[97]	_	_
14-20	1838-1842	lung	object|abstract[97]	new|new[97]	_	_
14-21	1843-1849	sounds	abstract[97]	new[97]	_	_
14-22	1850-1851	,	_	_	_	_
14-23	1852-1855	and	_	_	_	_
14-24	1856-1864	enlarged	_	_	_	_
14-25	1865-1875	mandibular	object[99]	new[99]	_	_
14-26	1876-1881	lymph	person|object[99]	new|new[99]	_	_
14-27	1882-1887	nodes	object[99]	new[99]	_	_
14-28	1888-1889	,	_	_	_	_
14-29	1890-1895	which	_	_	_	_
14-30	1896-1908	corresponded	_	_	_	_
14-31	1909-1913	with	_	_	_	_
14-32	1914-1916	an	abstract[100]	new[100]	_	_
14-33	1917-1925	increase	abstract[100]	new[100]	_	_
14-34	1926-1928	in	abstract[100]	new[100]	_	_
14-35	1929-1937	antibody	abstract[100]|substance|abstract[102]	new[100]|new|new[102]	_	_
14-36	1938-1944	titres	abstract[100]|abstract[102]	new[100]|new[102]	_	_
14-37	1945-1952	against	abstract[100]|abstract[102]	new[100]|new[102]	_	_
14-38	1953-1956	the	abstract[100]|abstract[102]|abstract[103]	new[100]|new[102]|giv[103]	coref	16-9[111_103]
14-39	1957-1962	virus	abstract[100]|abstract[102]|abstract[103]	new[100]|new[102]|giv[103]	_	_
14-40	1963-1964	.	_	_	_	_

#Text=The clinical signs observed during this study were associated with the seroconversions and there was no evidence of other viral infections .
15-1	1965-1968	The	abstract[104]	giv[104]	coref	22-23[174_104]
15-2	1969-1977	clinical	abstract[104]	giv[104]	_	_
15-3	1978-1983	signs	abstract[104]	giv[104]	_	_
15-4	1984-1992	observed	_	_	_	_
15-5	1993-1999	during	_	_	_	_
15-6	2000-2004	this	abstract[105]	giv[105]	coref	17-6[121_105]
15-7	2005-2010	study	abstract[105]	giv[105]	_	_
15-8	2011-2015	were	_	_	_	_
15-9	2016-2026	associated	_	_	_	_
15-10	2027-2031	with	_	_	_	_
15-11	2032-2035	the	abstract[106]	new[106]	coref	22-8[170_106]
15-12	2036-2051	seroconversions	abstract[106]	new[106]	_	_
15-13	2052-2055	and	_	_	_	_
15-14	2056-2061	there	_	_	_	_
15-15	2062-2065	was	_	_	_	_
15-16	2066-2068	no	abstract[107]	new[107]	_	_
15-17	2069-2077	evidence	abstract[107]	new[107]	_	_
15-18	2078-2080	of	abstract[107]	new[107]	_	_
15-19	2081-2086	other	abstract[107]|abstract[108]	new[107]|new[108]	_	_
15-20	2087-2092	viral	abstract[107]|abstract[108]	new[107]|new[108]	_	_
15-21	2093-2103	infections	abstract[107]|abstract[108]	new[107]|new[108]	_	_
15-22	2104-2105	.	_	_	_	_

#Text=ERAV may have been the primary cause of the respiratory disease and subsequent training loss , but it is more likely that the virus was a contributory factor in a multifactorial disorder .
16-1	2106-2110	ERAV	abstract	giv	coref	16-5[110_0]
16-2	2111-2114	may	_	_	_	_
16-3	2115-2119	have	_	_	_	_
16-4	2120-2124	been	_	_	_	_
16-5	2125-2128	the	abstract[110]	giv[110]	coref	19-24[0_110]
16-6	2129-2136	primary	abstract[110]	giv[110]	_	_
16-7	2137-2142	cause	abstract[110]	giv[110]	_	_
16-8	2143-2145	of	abstract[110]	giv[110]	_	_
16-9	2146-2149	the	abstract[110]|abstract[111]|abstract[112]	giv[110]|giv[111]|giv[112]	coref|coref	16-23[116_111]|16-23[116_111]
16-10	2150-2161	respiratory	abstract[110]|abstract[111]|abstract[112]	giv[110]|giv[111]|giv[112]	_	_
16-11	2162-2169	disease	abstract[110]|abstract[111]|abstract[112]	giv[110]|giv[111]|giv[112]	_	_
16-12	2170-2173	and	abstract[110]|abstract[112]	giv[110]|giv[112]	_	_
16-13	2174-2184	subsequent	abstract[110]|abstract[112]|abstract[114]	giv[110]|giv[112]|giv[114]	_	_
16-14	2185-2193	training	abstract[110]|abstract[112]|abstract|abstract[114]	giv[110]|giv[112]|giv|giv[114]	coref	20-19
16-15	2194-2198	loss	abstract[110]|abstract[112]|abstract[114]	giv[110]|giv[112]|giv[114]	_	_
16-16	2199-2200	,	_	_	_	_
16-17	2201-2204	but	_	_	_	_
16-18	2205-2207	it	abstract	new	cata	16-18[0_117]
16-19	2208-2210	is	_	_	_	_
16-20	2211-2215	more	_	_	_	_
16-21	2216-2222	likely	_	_	_	_
16-22	2223-2227	that	abstract[117]	new[117]	_	_
16-23	2228-2231	the	abstract[116]|abstract[117]	giv[116]|new[117]	coref	21-22[0_116]
16-24	2232-2237	virus	abstract[116]|abstract[117]	giv[116]|new[117]	_	_
16-25	2238-2241	was	abstract[117]	new[117]	_	_
16-26	2242-2243	a	abstract[117]	new[117]	_	_
16-27	2244-2256	contributory	abstract[117]	new[117]	_	_
16-28	2257-2263	factor	abstract[117]	new[117]	_	_
16-29	2264-2266	in	abstract[117]	new[117]	_	_
16-30	2267-2268	a	abstract[117]|abstract[118]	new[117]|new[118]	_	_
16-31	2269-2283	multifactorial	abstract[117]|abstract[118]	new[117]|new[118]	_	_
16-32	2284-2292	disorder	abstract[117]|abstract[118]	new[117]|new[118]	_	_
16-33	2293-2294	.	_	_	_	_

#Text=The serology tests used in this study are sensitive and specific , but it is possible that other less common viruses , such as adenovirus and coronavirus , or even as-yet unidentified equine viruses , may have played a role .
17-1	2295-2298	The	abstract[120]	new[120]	_	_
17-2	2299-2307	serology	abstract|abstract[120]	new|new[120]	coref	25-2
17-3	2308-2313	tests	abstract[120]	new[120]	_	_
17-4	2314-2318	used	_	_	_	_
17-5	2319-2321	in	_	_	_	_
17-6	2322-2326	this	abstract[121]	giv[121]	coref	19-16[142_121]
17-7	2327-2332	study	abstract[121]	giv[121]	_	_
17-8	2333-2336	are	_	_	_	_
17-9	2337-2346	sensitive	_	_	_	_
17-10	2347-2350	and	_	_	_	_
17-11	2351-2359	specific	_	_	_	_
17-12	2360-2361	,	_	_	_	_
17-13	2362-2365	but	_	_	_	_
17-14	2366-2368	it	event	new	cata	17-14[0_128]
17-15	2369-2371	is	_	_	_	_
17-16	2372-2380	possible	_	_	_	_
17-17	2381-2385	that	event[128]	new[128]	_	_
17-18	2386-2391	other	abstract[123]|event[128]	new[123]|new[128]	coref	18-27[0_123]
17-19	2392-2396	less	abstract[123]|event[128]	new[123]|new[128]	_	_
17-20	2397-2403	common	abstract[123]|event[128]	new[123]|new[128]	_	_
17-21	2404-2411	viruses	abstract[123]|event[128]	new[123]|new[128]	_	_
17-22	2412-2413	,	abstract[123]|event[128]	new[123]|new[128]	_	_
17-23	2414-2418	such	abstract[123]|event[128]	new[123]|new[128]	_	_
17-24	2419-2421	as	abstract[123]|event[128]	new[123]|new[128]	_	_
17-25	2422-2432	adenovirus	abstract[123]|plant|event[128]	new[123]|new|new[128]	_	_
17-26	2433-2436	and	abstract[123]|event[128]	new[123]|new[128]	_	_
17-27	2437-2448	coronavirus	abstract[123]|object|event[128]	new[123]|new|new[128]	_	_
17-28	2449-2450	,	abstract[123]|event[128]	new[123]|new[128]	_	_
17-29	2451-2453	or	abstract[123]|event[128]	new[123]|new[128]	_	_
17-30	2454-2458	even	abstract[123]|object[127]|event[128]	new[123]|new[127]|new[128]	_	_
17-31	2459-2465	as-yet	abstract[123]|object[127]|event[128]	new[123]|new[127]|new[128]	_	_
17-32	2466-2478	unidentified	abstract[123]|object[127]|event[128]	new[123]|new[127]|new[128]	_	_
17-33	2479-2485	equine	abstract[123]|object|object[127]|event[128]	new[123]|new|new[127]|new[128]	_	_
17-34	2486-2493	viruses	abstract[123]|object[127]|event[128]	new[123]|new[127]|new[128]	_	_
17-35	2494-2495	,	event[128]	new[128]	_	_
17-36	2496-2499	may	event[128]	new[128]	_	_
17-37	2500-2504	have	event[128]	new[128]	_	_
17-38	2505-2511	played	event[128]	new[128]	_	_
17-39	2512-2513	a	event[128]|abstract[129]	new[128]|new[129]	coref	19-3[138_129]
17-40	2514-2518	role	event[128]|abstract[129]	new[128]|new[129]	_	_
17-41	2519-2520	.	_	_	_	_

#Text=Previous studies have demonstrated the complexity of poor performance syndrome in Thoroughbred racehorses and that bacteria are more common and may be aetiologically more important than viruses .
18-1	2521-2529	Previous	abstract[130]	new[130]	coref	24-1[186_130]
18-2	2530-2537	studies	abstract[130]	new[130]	_	_
18-3	2538-2542	have	_	_	_	_
18-4	2543-2555	demonstrated	_	_	_	_
18-5	2556-2559	the	abstract[131]	new[131]	_	_
18-6	2560-2570	complexity	abstract[131]	new[131]	_	_
18-7	2571-2573	of	abstract[131]	new[131]	_	_
18-8	2574-2578	poor	abstract[131]|abstract[133]	new[131]|new[133]	_	_
18-9	2579-2590	performance	abstract[131]|abstract|abstract[133]	new[131]|new|new[133]	coref	23-25[185_0]
18-10	2591-2599	syndrome	abstract[131]|abstract[133]	new[131]|new[133]	_	_
18-11	2600-2602	in	abstract[131]|abstract[133]	new[131]|new[133]	_	_
18-12	2603-2615	Thoroughbred	abstract[131]|abstract[133]|animal|animal[135]	new[131]|new[133]|new|giv[135]	_	_
18-13	2616-2626	racehorses	abstract[131]|abstract[133]|animal[135]	new[131]|new[133]|giv[135]	_	_
18-14	2627-2630	and	_	_	_	_
18-15	2631-2635	that	_	_	_	_
18-16	2636-2644	bacteria	animal	new	_	_
18-17	2645-2648	are	_	_	_	_
18-18	2649-2653	more	_	_	_	_
18-19	2654-2660	common	_	_	_	_
18-20	2661-2664	and	_	_	_	_
18-21	2665-2668	may	_	_	_	_
18-22	2669-2671	be	_	_	_	_
18-23	2672-2686	aetiologically	_	_	_	_
18-24	2687-2691	more	_	_	_	_
18-25	2692-2701	important	_	_	_	_
18-26	2702-2706	than	_	_	_	_
18-27	2707-2714	viruses	abstract	giv	_	_
18-28	2715-2716	.	_	_	_	_

#Text=Unfortunately , the possible role of bacterial infection as a cofactor was not investigated in this study and the statistically significant association of ERAV with failure to race during the study period does not conclusively demonstrate causation .
19-1	2717-2730	Unfortunately	_	_	_	_
19-2	2731-2732	,	_	_	_	_
19-3	2733-2736	the	abstract[138]	giv[138]	_	_
19-4	2737-2745	possible	abstract[138]	giv[138]	_	_
19-5	2746-2750	role	abstract[138]	giv[138]	_	_
19-6	2751-2753	of	abstract[138]	giv[138]	_	_
19-7	2754-2763	bacterial	abstract[138]|object|abstract[140]	giv[138]|new|giv[140]	coref|coref	24-6[188_140]|24-6[188_140]
19-8	2764-2773	infection	abstract[138]|abstract[140]	giv[138]|giv[140]	_	_
19-9	2774-2776	as	_	_	_	_
19-10	2777-2778	a	abstract[141]	new[141]	_	_
19-11	2779-2787	cofactor	abstract[141]	new[141]	_	_
19-12	2788-2791	was	_	_	_	_
19-13	2792-2795	not	_	_	_	_
19-14	2796-2808	investigated	_	_	_	_
19-15	2809-2811	in	_	_	_	_
19-16	2812-2816	this	abstract[142]	giv[142]	coref	19-31[0_142]
19-17	2817-2822	study	abstract[142]	giv[142]	_	_
19-18	2823-2826	and	_	_	_	_
19-19	2827-2830	the	abstract[143]	giv[143]	_	_
19-20	2831-2844	statistically	abstract[143]	giv[143]	_	_
19-21	2845-2856	significant	abstract[143]	giv[143]	_	_
19-22	2857-2868	association	abstract[143]	giv[143]	_	_
19-23	2869-2871	of	abstract[143]	giv[143]	_	_
19-24	2872-2876	ERAV	abstract[143]|abstract	giv[143]|giv	coref	21-6
19-25	2877-2881	with	abstract[143]	giv[143]	_	_
19-26	2882-2889	failure	abstract[143]|abstract[145]	giv[143]|giv[145]	_	_
19-27	2890-2892	to	abstract[143]|abstract[145]	giv[143]|giv[145]	_	_
19-28	2893-2897	race	abstract[143]|abstract[145]|abstract[146]	giv[143]|giv[145]|giv[146]	_	_
19-29	2898-2904	during	abstract[143]|abstract[145]|abstract[146]	giv[143]|giv[145]|giv[146]	_	_
19-30	2905-2908	the	abstract[143]|abstract[145]|abstract[146]|time[148]	giv[143]|giv[145]|giv[146]|giv[148]	coref	22-32[177_148]
19-31	2909-2914	study	abstract[143]|abstract[145]|abstract[146]|abstract|time[148]	giv[143]|giv[145]|giv[146]|giv|giv[148]	coref	22-33
19-32	2915-2921	period	abstract[143]|abstract[145]|abstract[146]|time[148]	giv[143]|giv[145]|giv[146]|giv[148]	_	_
19-33	2922-2926	does	_	_	_	_
19-34	2927-2930	not	_	_	_	_
19-35	2931-2943	conclusively	_	_	_	_
19-36	2944-2955	demonstrate	_	_	_	_
19-37	2956-2965	causation	abstract	new	_	_
19-38	2966-2967	.	_	_	_	_

#Text=However , it is essential to determine which infectious agents are prevalent in populations that suffer interruption to training as a first step in assessing their true impact .
20-1	2968-2975	However	_	_	_	_
20-2	2976-2977	,	_	_	_	_
20-3	2978-2980	it	abstract	new	cata	20-3[0_151]
20-4	2981-2983	is	_	_	_	_
20-5	2984-2993	essential	_	_	_	_
20-6	2994-2996	to	abstract[151]	new[151]	_	_
20-7	2997-3006	determine	abstract[151]	new[151]	_	_
20-8	3007-3012	which	abstract[151]	new[151]	_	_
20-9	3013-3023	infectious	abstract[151]|person[152]	new[151]|new[152]	_	_
20-10	3024-3030	agents	abstract[151]|person[152]	new[151]|new[152]	_	_
20-11	3031-3034	are	abstract[151]	new[151]	_	_
20-12	3035-3044	prevalent	abstract[151]	new[151]	_	_
20-13	3045-3047	in	_	_	_	_
20-14	3048-3059	populations	abstract	new	ana	20-26
20-15	3060-3064	that	_	_	_	_
20-16	3065-3071	suffer	_	_	_	_
20-17	3072-3084	interruption	abstract	giv	_	_
20-18	3085-3087	to	_	_	_	_
20-19	3088-3096	training	abstract	giv	coref	21-16[165_0]
20-20	3097-3099	as	_	_	_	_
20-21	3100-3101	a	_	_	_	_
20-22	3102-3107	first	_	_	_	_
20-23	3108-3112	step	_	_	_	_
20-24	3113-3115	in	_	_	_	_
20-25	3116-3125	assessing	_	_	_	_
20-26	3126-3131	their	abstract|abstract[157]	giv|new[157]	coref|coref	26-7[202_0]|26-7[202_0]
20-27	3132-3136	true	abstract[157]	new[157]	_	_
20-28	3137-3143	impact	abstract[157]	new[157]	_	_
20-29	3144-3145	.	_	_	_	_

#Text=Lack of previous exposure to ERAV and stress associated with the change of environment and intensive training may have contributed to disease susceptibility .
21-1	3146-3150	Lack	abstract[158]	new[158]	_	_
21-2	3151-3153	of	abstract[158]	new[158]	_	_
21-3	3154-3162	previous	abstract[158]|abstract[159]	new[158]|giv[159]	_	_
21-4	3163-3171	exposure	abstract[158]|abstract[159]	new[158]|giv[159]	_	_
21-5	3172-3174	to	abstract[158]|abstract[159]	new[158]|giv[159]	_	_
21-6	3175-3179	ERAV	abstract[158]|abstract[159]|abstract|abstract[161]	new[158]|giv[159]|giv|new[161]	coref|coref|coref|coref	22-11|32-3[247_161]|22-11|32-3[247_161]
21-7	3180-3183	and	abstract[158]|abstract[159]|abstract[161]	new[158]|giv[159]|new[161]	_	_
21-8	3184-3190	stress	abstract[158]|abstract[159]|abstract[161]|abstract	new[158]|giv[159]|new[161]|new	_	_
21-9	3191-3201	associated	_	_	_	_
21-10	3202-3206	with	_	_	_	_
21-11	3207-3210	the	abstract[163]	new[163]	_	_
21-12	3211-3217	change	abstract[163]	new[163]	_	_
21-13	3218-3220	of	abstract[163]	new[163]	_	_
21-14	3221-3232	environment	abstract[163]|abstract	new[163]|giv	_	_
21-15	3233-3236	and	abstract[163]	new[163]	_	_
21-16	3237-3246	intensive	abstract[163]|abstract[165]	new[163]|giv[165]	coref	28-48[0_165]
21-17	3247-3255	training	abstract[163]|abstract[165]	new[163]|giv[165]	_	_
21-18	3256-3259	may	_	_	_	_
21-19	3260-3264	have	_	_	_	_
21-20	3265-3276	contributed	_	_	_	_
21-21	3277-3279	to	_	_	_	_
21-22	3280-3287	disease	abstract|abstract[167]	giv|giv[167]	coref|coref	22-26[175_0]|22-26[175_0]
21-23	3288-3302	susceptibility	abstract[167]	giv[167]	_	_
21-24	3303-3304	.	_	_	_	_

#Text=In contrast to the two-year-old horses , no seroconversions to ERAV were observed in the three-year-old horses — they remained free of any signs of respiratory disease and raced successfully throughout the study period .
22-1	3305-3307	In	_	_	_	_
22-2	3308-3316	contrast	abstract[168]	new[168]	_	_
22-3	3317-3319	to	abstract[168]	new[168]	_	_
22-4	3320-3323	the	abstract[168]|animal[169]	new[168]|giv[169]	coref	22-15[172_169]
22-5	3324-3336	two-year-old	abstract[168]|animal[169]	new[168]|giv[169]	_	_
22-6	3337-3343	horses	abstract[168]|animal[169]	new[168]|giv[169]	_	_
22-7	3344-3345	,	_	_	_	_
22-8	3346-3348	no	abstract[170]	giv[170]	ana	22-19[0_170]
22-9	3349-3364	seroconversions	abstract[170]	giv[170]	_	_
22-10	3365-3367	to	abstract[170]	giv[170]	_	_
22-11	3368-3372	ERAV	abstract[170]|abstract	giv[170]|giv	coref	23-4[179_0]
22-12	3373-3377	were	_	_	_	_
22-13	3378-3386	observed	_	_	_	_
22-14	3387-3389	in	_	_	_	_
22-15	3390-3393	the	animal[172]	giv[172]	coref	23-15[183_172]
22-16	3394-3408	three-year-old	animal[172]	giv[172]	_	_
22-17	3409-3415	horses	animal[172]	giv[172]	_	_
22-18	3416-3417	—	_	_	_	_
22-19	3418-3422	they	abstract	giv	_	_
22-20	3423-3431	remained	_	_	_	_
22-21	3432-3436	free	_	_	_	_
22-22	3437-3439	of	_	_	_	_
22-23	3440-3443	any	abstract[174]	giv[174]	coref	23-22[184_174]
22-24	3444-3449	signs	abstract[174]	giv[174]	_	_
22-25	3450-3452	of	abstract[174]	giv[174]	_	_
22-26	3453-3464	respiratory	abstract[174]|abstract[175]	giv[174]|giv[175]	coref	26-13[0_175]
22-27	3465-3472	disease	abstract[174]|abstract[175]	giv[174]|giv[175]	_	_
22-28	3473-3476	and	_	_	_	_
22-29	3477-3482	raced	_	_	_	_
22-30	3483-3495	successfully	_	_	_	_
22-31	3496-3506	throughout	_	_	_	_
22-32	3507-3510	the	time[177]	giv[177]	coref	25-13[197_177]
22-33	3511-3516	study	abstract|time[177]	giv|giv[177]	coref	25-16
22-34	3517-3523	period	time[177]	giv[177]	_	_
22-35	3524-3525	.	_	_	_	_

#Text=The seroconversion to ERAV in the four-year-old horse and the reinfection of two of the younger horses were not associated with clinical signs or reduced performance .
23-1	3526-3529	The	abstract[178]	new[178]	_	_
23-2	3530-3544	seroconversion	abstract[178]	new[178]	_	_
23-3	3545-3547	to	abstract[178]	new[178]	_	_
23-4	3548-3552	ERAV	abstract[178]|abstract[179]	new[178]|giv[179]	coref	24-6[0_179]
23-5	3553-3555	in	abstract[178]|abstract[179]	new[178]|giv[179]	_	_
23-6	3556-3559	the	abstract[178]|abstract[179]|animal[180]	new[178]|giv[179]|new[180]	coref	26-7[0_180]
23-7	3560-3573	four-year-old	abstract[178]|abstract[179]|animal[180]	new[178]|giv[179]|new[180]	_	_
23-8	3574-3579	horse	abstract[178]|abstract[179]|animal[180]	new[178]|giv[179]|new[180]	_	_
23-9	3580-3583	and	_	_	_	_
23-10	3584-3587	the	event[181]	new[181]	coref	24-14[0_181]
23-11	3588-3599	reinfection	event[181]	new[181]	_	_
23-12	3600-3602	of	event[181]	new[181]	_	_
23-13	3603-3606	two	event[181]|person[182]	new[181]|new[182]	_	_
23-14	3607-3609	of	event[181]|person[182]	new[181]|new[182]	_	_
23-15	3610-3613	the	event[181]|person[182]|animal[183]	new[181]|new[182]|giv[183]	coref	26-16[0_183]
23-16	3614-3621	younger	event[181]|person[182]|animal[183]	new[181]|new[182]|giv[183]	_	_
23-17	3622-3628	horses	event[181]|person[182]|animal[183]	new[181]|new[182]|giv[183]	_	_
23-18	3629-3633	were	_	_	_	_
23-19	3634-3637	not	_	_	_	_
23-20	3638-3648	associated	_	_	_	_
23-21	3649-3653	with	_	_	_	_
23-22	3654-3662	clinical	abstract[184]	giv[184]	_	_
23-23	3663-3668	signs	abstract[184]	giv[184]	_	_
23-24	3669-3671	or	abstract[184]	giv[184]	_	_
23-25	3672-3679	reduced	abstract[184]|abstract[185]	giv[184]|giv[185]	_	_
23-26	3680-3691	performance	abstract[184]|abstract[185]	giv[184]|giv[185]	_	_
23-27	3692-3693	.	_	_	_	_

#Text=Experimental studies have indicated that ERAV infection stimulated a protective response and that reinfection is asymptomatic .
24-1	3694-3706	Experimental	abstract[186]	giv[186]	_	_
24-2	3707-3714	studies	abstract[186]	giv[186]	_	_
24-3	3715-3719	have	_	_	_	_
24-4	3720-3729	indicated	_	_	_	_
24-5	3730-3734	that	_	_	_	_
24-6	3735-3739	ERAV	object|abstract[188]	giv|giv[188]	coref|coref|coref|coref	25-6|26-4[200_188]|25-6|26-4[200_188]
24-7	3740-3749	infection	abstract[188]	giv[188]	_	_
24-8	3750-3760	stimulated	_	_	_	_
24-9	3761-3762	a	abstract[189]	new[189]	_	_
24-10	3763-3773	protective	abstract[189]	new[189]	_	_
24-11	3774-3782	response	abstract[189]	new[189]	_	_
24-12	3783-3786	and	_	_	_	_
24-13	3787-3791	that	_	_	_	_
24-14	3792-3803	reinfection	event	giv	_	_
24-15	3804-3806	is	_	_	_	_
24-16	3807-3819	asymptomatic	_	_	_	_
24-17	3820-3821	.	_	_	_	_

#Text=The serology results indicate that ERAV was circulating in the yard throughout the six month study period .
25-1	3822-3825	The	abstract[192]	giv[192]	_	_
25-2	3826-3834	serology	abstract|abstract[192]	giv|giv[192]	_	_
25-3	3835-3842	results	abstract[192]	giv[192]	_	_
25-4	3843-3851	indicate	_	_	_	_
25-5	3852-3856	that	_	_	_	_
25-6	3857-3861	ERAV	abstract	giv	coref	26-4
25-7	3862-3865	was	_	_	_	_
25-8	3866-3877	circulating	_	_	_	_
25-9	3878-3880	in	_	_	_	_
25-10	3881-3884	the	place[194]	giv[194]	_	_
25-11	3885-3889	yard	place[194]	giv[194]	_	_
25-12	3890-3900	throughout	_	_	_	_
25-13	3901-3904	the	time[197]	giv[197]	coref	30-2[237_197]
25-14	3905-3908	six	time[195]|time[197]	new[195]|giv[197]	_	_
25-15	3909-3914	month	time[195]|time[197]	new[195]|giv[197]	_	_
25-16	3915-3920	study	abstract|time[197]	giv|giv[197]	coref	30-3
25-17	3921-3927	period	time[197]	giv[197]	_	_
25-18	3928-3929	.	_	_	_	_

#Text=The dynamics of ERAV infection in horse populations are poorly understood but virus persists in horses even in the presence of high levels of antibodies .
26-1	3930-3933	The	abstract[198]	new[198]	_	_
26-2	3934-3942	dynamics	abstract[198]	new[198]	_	_
26-3	3943-3945	of	abstract[198]	new[198]	_	_
26-4	3946-3950	ERAV	abstract[198]|object|abstract[200]	new[198]|giv|giv[200]	coref|coref|coref|coref	27-1|27-9[211_200]|27-1|27-9[211_200]
26-5	3951-3960	infection	abstract[198]|abstract[200]	new[198]|giv[200]	_	_
26-6	3961-3963	in	abstract[198]|abstract[200]	new[198]|giv[200]	_	_
26-7	3964-3969	horse	abstract[198]|abstract[200]|animal|abstract[202]	new[198]|giv[200]|giv|giv[202]	coref|coref	30-6[238_0]|30-6[238_0]
26-8	3970-3981	populations	abstract[198]|abstract[200]|abstract[202]	new[198]|giv[200]|giv[202]	_	_
26-9	3982-3985	are	_	_	_	_
26-10	3986-3992	poorly	_	_	_	_
26-11	3993-4003	understood	_	_	_	_
26-12	4004-4007	but	_	_	_	_
26-13	4008-4013	virus	abstract	giv	_	_
26-14	4014-4022	persists	_	_	_	_
26-15	4023-4025	in	_	_	_	_
26-16	4026-4032	horses	animal	giv	_	_
26-17	4033-4037	even	abstract[205]	new[205]	_	_
26-18	4038-4040	in	abstract[205]	new[205]	_	_
26-19	4041-4044	the	abstract[205]	new[205]	_	_
26-20	4045-4053	presence	abstract[205]	new[205]	_	_
26-21	4054-4056	of	abstract[205]	new[205]	_	_
26-22	4057-4061	high	abstract[205]|abstract[206]	new[205]|new[206]	_	_
26-23	4062-4068	levels	abstract[205]|abstract[206]	new[205]|new[206]	_	_
26-24	4069-4071	of	abstract[205]|abstract[206]	new[205]|new[206]	_	_
26-25	4072-4082	antibodies	abstract[205]|abstract[206]|substance	new[205]|new[206]|new	_	_
26-26	4083-4084	.	_	_	_	_

#Text=ERAV can be isolated from the blood for a few days post infection and from the nasopharynx and faeces for up to a month .
27-1	4085-4089	ERAV	abstract	giv	coref	28-10[219_0]
27-2	4090-4093	can	_	_	_	_
27-3	4094-4096	be	_	_	_	_
27-4	4097-4105	isolated	_	_	_	_
27-5	4106-4110	from	_	_	_	_
27-6	4111-4114	the	substance[209]	new[209]	_	_
27-7	4115-4120	blood	substance[209]	new[209]	_	_
27-8	4121-4124	for	_	_	_	_
27-9	4125-4126	a	abstract[211]	giv[211]	_	_
27-10	4127-4130	few	time[210]|abstract[211]	new[210]|giv[211]	_	_
27-11	4131-4135	days	time[210]|abstract[211]	new[210]|giv[211]	_	_
27-12	4136-4140	post	abstract[211]	giv[211]	_	_
27-13	4141-4150	infection	abstract[211]	giv[211]	_	_
27-14	4151-4154	and	_	_	_	_
27-15	4155-4159	from	_	_	_	_
27-16	4160-4163	the	object[212]	new[212]	_	_
27-17	4164-4175	nasopharynx	object[212]	new[212]	_	_
27-18	4176-4179	and	_	_	_	_
27-19	4180-4186	faeces	object[213]	new[213]	_	_
27-20	4187-4190	for	object[213]	new[213]	_	_
27-21	4191-4193	up	object[213]	new[213]	_	_
27-22	4194-4196	to	object[213]	new[213]	_	_
27-23	4197-4198	a	object[213]|time[214]	new[213]|new[214]	_	_
27-24	4199-4204	month	object[213]|time[214]	new[213]|new[214]	_	_
27-25	4205-4206	.	_	_	_	_

#Text=Studies in the USA , Ireland and Australia detected ERAV in post-race urine samples at frequencies of 17 % , 29 % and 23 % , respectively , which led to a suggestion that the persistent presence of ERAV in urine may contribute to its maintenance in training yards .
28-1	4207-4214	Studies	event[215]	new[215]	_	_
28-2	4215-4217	in	event[215]	new[215]	_	_
28-3	4218-4221	the	event[215]|place[216]	new[215]|new[216]	_	_
28-4	4222-4225	USA	event[215]|place[216]	new[215]|new[216]	_	_
28-5	4226-4227	,	event[215]	new[215]	_	_
28-6	4228-4235	Ireland	event[215]|place	new[215]|giv	coref	31-9
28-7	4236-4239	and	event[215]	new[215]	_	_
28-8	4240-4249	Australia	event[215]|place	new[215]|giv	_	_
28-9	4250-4258	detected	_	_	_	_
28-10	4259-4263	ERAV	abstract[219]	giv[219]	coref	28-39[0_219]
28-11	4264-4266	in	abstract[219]	giv[219]	_	_
28-12	4267-4276	post-race	abstract[219]|object[221]	giv[219]|new[221]	_	_
28-13	4277-4282	urine	abstract[219]|substance|object[221]	giv[219]|new|new[221]	coref	28-41
28-14	4283-4290	samples	abstract[219]|object[221]	giv[219]|new[221]	_	_
28-15	4291-4293	at	abstract[219]|object[221]	giv[219]|new[221]	_	_
28-16	4294-4305	frequencies	abstract[219]|object[221]|quantity[222]	giv[219]|new[221]|new[222]	_	_
28-17	4306-4308	of	abstract[219]|object[221]|quantity[222]	giv[219]|new[221]|new[222]	_	_
28-18	4309-4311	17	abstract[219]|object[221]|quantity[222]|quantity[223]	giv[219]|new[221]|new[222]|new[223]	_	_
28-19	4312-4313	%	abstract[219]|object[221]|quantity[222]|quantity[223]	giv[219]|new[221]|new[222]|new[223]	_	_
28-20	4314-4315	,	abstract[219]|object[221]|quantity[222]	giv[219]|new[221]|new[222]	_	_
28-21	4316-4318	29	abstract[219]|object[221]|quantity[222]|quantity[224]	giv[219]|new[221]|new[222]|giv[224]	_	_
28-22	4319-4320	%	abstract[219]|object[221]|quantity[222]|quantity[224]	giv[219]|new[221]|new[222]|giv[224]	_	_
28-23	4321-4324	and	abstract[219]|object[221]|quantity[222]	giv[219]|new[221]|new[222]	_	_
28-24	4325-4327	23	abstract[219]|object[221]|quantity[222]|quantity[225]	giv[219]|new[221]|new[222]|new[225]	_	_
28-25	4328-4329	%	abstract[219]|object[221]|quantity[222]|quantity[225]	giv[219]|new[221]|new[222]|new[225]	_	_
28-26	4330-4331	,	_	_	_	_
28-27	4332-4344	respectively	_	_	_	_
28-28	4345-4346	,	_	_	_	_
28-29	4347-4352	which	_	_	_	_
28-30	4353-4356	led	_	_	_	_
28-31	4357-4359	to	_	_	_	_
28-32	4360-4361	a	abstract[226]	new[226]	_	_
28-33	4362-4372	suggestion	abstract[226]	new[226]	_	_
28-34	4373-4377	that	abstract[226]	new[226]	_	_
28-35	4378-4381	the	abstract[226]|abstract[227]	new[226]|new[227]	_	_
28-36	4382-4392	persistent	abstract[226]|abstract[227]	new[226]|new[227]	_	_
28-37	4393-4401	presence	abstract[226]|abstract[227]	new[226]|new[227]	_	_
28-38	4402-4404	of	abstract[226]|abstract[227]	new[226]|new[227]	_	_
28-39	4405-4409	ERAV	abstract[226]|abstract[227]|abstract	new[226]|new[227]|giv	coref	31-12
28-40	4410-4412	in	abstract[226]|abstract[227]	new[226]|new[227]	_	_
28-41	4413-4418	urine	abstract[226]|abstract[227]|substance	new[226]|new[227]|giv	ana	28-45
28-42	4419-4422	may	abstract[226]	new[226]	_	_
28-43	4423-4433	contribute	abstract[226]	new[226]	_	_
28-44	4434-4436	to	_	_	_	_
28-45	4437-4440	its	substance|abstract[231]	giv|new[231]	coref|coref	29-6|29-6
28-46	4441-4452	maintenance	abstract[231]	new[231]	_	_
28-47	4453-4455	in	abstract[231]	new[231]	_	_
28-48	4456-4464	training	abstract[231]|abstract|place[233]	new[231]|giv|new[233]	_	_
28-49	4465-4470	yards	abstract[231]|place[233]	new[231]|new[233]	_	_
28-50	4471-4472	.	_	_	_	_

#Text=ERBV was not detected in urine .
29-1	4473-4477	ERBV	abstract	new	coref	30-11
29-2	4478-4481	was	_	_	_	_
29-3	4482-4485	not	_	_	_	_
29-4	4486-4494	detected	_	_	_	_
29-5	4495-4497	in	_	_	_	_
29-6	4498-4503	urine	substance	giv	_	_
29-7	4504-4505	.	_	_	_	_

#Text=During this study period , only one horse seroconverted to ERBV .
30-1	4506-4512	During	_	_	_	_
30-2	4513-4517	this	time[237]	giv[237]	_	_
30-3	4518-4523	study	abstract|time[237]	giv|giv[237]	coref	31-5[241_0]
30-4	4524-4530	period	time[237]	giv[237]	_	_
30-5	4531-4532	,	_	_	_	_
30-6	4533-4537	only	animal[238]	giv[238]	_	_
30-7	4538-4541	one	animal[238]	giv[238]	_	_
30-8	4542-4547	horse	animal[238]	giv[238]	_	_
30-9	4548-4561	seroconverted	_	_	_	_
30-10	4562-4564	to	_	_	_	_
30-11	4565-4569	ERBV	abstract	giv	ana	31-1
30-12	4570-4571	.	_	_	_	_

#Text=This was consistent with an earlier study in Ireland in which ERAV was found to be more commonly detected than ERBV .
31-1	4572-4576	This	abstract	giv	coref	31-21
31-2	4577-4580	was	_	_	_	_
31-3	4581-4591	consistent	_	_	_	_
31-4	4592-4596	with	_	_	_	_
31-5	4597-4599	an	abstract[241]	giv[241]	_	_
31-6	4600-4607	earlier	abstract[241]	giv[241]	_	_
31-7	4608-4613	study	abstract[241]	giv[241]	_	_
31-8	4614-4616	in	abstract[241]	giv[241]	_	_
31-9	4617-4624	Ireland	abstract[241]|place	giv[241]|giv	_	_
31-10	4625-4627	in	_	_	_	_
31-11	4628-4633	which	_	_	_	_
31-12	4634-4638	ERAV	abstract	giv	coref	32-3
31-13	4639-4642	was	_	_	_	_
31-14	4643-4648	found	_	_	_	_
31-15	4649-4651	to	_	_	_	_
31-16	4652-4654	be	_	_	_	_
31-17	4655-4659	more	_	_	_	_
31-18	4660-4668	commonly	_	_	_	_
31-19	4669-4677	detected	_	_	_	_
31-20	4678-4682	than	_	_	_	_
31-21	4683-4687	ERBV	object	giv	coref	32-5
31-22	4688-4689	.	_	_	_	_

#Text=Co-circulation of ERAV and ERBV was also reported previously .
32-1	4690-4704	Co-circulation	abstract[245]	new[245]	_	_
32-2	4705-4707	of	abstract[245]	new[245]	_	_
32-3	4708-4712	ERAV	abstract[245]|abstract|abstract[247]	new[245]|giv|giv[247]	_	_
32-4	4713-4716	and	abstract[245]|abstract[247]	new[245]|giv[247]	_	_
32-5	4717-4721	ERBV	abstract[245]|abstract[247]|organization	new[245]|giv[247]|giv	_	_
32-6	4722-4725	was	_	_	_	_
32-7	4726-4730	also	_	_	_	_
32-8	4731-4739	reported	_	_	_	_
32-9	4740-4750	previously	_	_	_	_
32-10	4751-4752	.	_	_	_	_
